Log in to search using one of your social media accounts:

 

Clinicopathologic Grand Rounds: Clinical Cases from the NIH Clinical Center: Gigantism: New Lessons from an Ancient Disease

Date: Wednesday, 11 29, 2017; Speaker: Andrew Demidowich, MD, Assistant Research Clinician, Office of the Clinical Director, NICHD; Prashant Chittiboina, MD, MPH, Assistant Clinical Investigator,, Neurosurgery Unit for Pituitary and Inheritable Diseases, NINDS; Constantine Stratakis, MD, D(Med)Sc, Scientific Director and, Senior Investigator, Section on Genetics and Endocrinology, NICHD; Building: Building 10 (Clinical Center); Lipsett Amphitheater; CME Credit; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events

Related Links:

To compare and describe the time to endocrine remission and new hypopituitarism among patients with growth hormone (GH) and adrenocorticotropic hormone (ACTH) secreting pituitary adenomas after radiosurgery after controlling for several known prognostic factors.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
Patients with acromegaly may be at continued risk for glucose disorders -- even after hypersecretion of growth hormone has been controlled.Journal of the Endocrine Society
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
AbstractPurposeTo assess baseline T2-weighted signal intensity (T2-WSI) of functional pituitary adenomas (FPA), and to investigate the relationship of baseline T2-WSI with clinical features, histopathological granulation patterns, and response to treatment in patients with acromegaly, prolactinoma and Cushing ’s disease (CD).MethodsSomatotroph adenomas (n  = 87), prolactinomas (n = 78) and corticotroph adenomas (n = 29) were included in the study. Baseline T2-WSI findings (grouped as hypo-, iso- and hyperintense) were compared with hormone levels, tumor diameter, granulation ...
Source: Pituitary - Category: Endocrinology Source Type: research
AbstractObjectiveTo determine aryl hydrocarbon interacting protein (AIP) gene variations andAIP and somatostatin receptor (SSTR) 1 –5 immunostaining in patients with apparently sporadic acromegaly with poor versus good response to somatostatin analogues (SRLs).MethodsA total of 94 patients (66 with poor and 28 with good response to SRLs) were screened for theAIP gene variations using Sanger sequencing. Immunostaining was performed in 60 tumors.ResultsSeveral variations, albeit some with undetermined significance, were detected, especially in poor responder patients. The prevalence ofAIP mutation was 2.1% in the whole...
Source: Pituitary - Category: Endocrinology Source Type: research
Conclusions A telomerase expression rate greater than 10% in the pituitary tumor tissue was associated with recurrence or progression of the PA, especially in the nonfunctioning cases.
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research
Conditions:   Acromegaly;   Growth Hormone Treatment;   Sleep Apnea;   Cardiovascular Diseases;   Bone Diseases Intervention:   Sponsor:   University of Aarhus Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractSurgery is the primary treatment for acromegaly. However, surgery may not be curative of some tumors, particularly invasive macroadenomas. Adjuvant radiation, specifically robotic stereotactic radiosurgery (rSRS), may improve the endocrine outcome. We retrospectively reviewed hormonal and radiological data of 22 acromegalic patients with invasive macroadenomas treated with rSRS at Stanford University Medical Center between 2000 and 2016. Prior to treatment, the tumor ’s median maximal diameter was 19 mm (2.5–50 mm). Cavernous sinus invasion occurred in 19 patients (86.3%) and compression of th...
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
Acromegaly results from the hypersecretion of growth hormone. Because of the low incidence rates of this disease worldwide, few clinical trials evaluating drug treatments have been conducted.
Source: Value in Health - Category: International Medicine & Public Health Authors: Tags: Systematic Review Source Type: research
This study aims to identify factors affecting the timing of remission and also to quantify the rate of late remission. This is a retrospective analysis of acromegaly patients who underwent SRS between 1988 and 2016. Early and late remissions were defined based on our prior median remission time of 29 months. The median imaging and endocrine follow-ups are 66 and 104.8 months, respectively. Multivariate analysis was conducted to analyze factors leading to late remission. A total number of 157 patients, of those 102 (64.9%) patients achieved remission. of those 102 patients, 62 patie nts (60.7%) had remission in le...
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
ConclusionThe most important factors affecting gonadal functions, excluding central hypogonadism, are hyperprolactinemia and the duration of the indolent period before diagnosis of acromegaly. AMH levels in the majority of patients were found to be lower than the expected age. Despite the decreased ovarian reserve, fertilization and normal birth can be achieved with careful surveillance.
Source: Endocrine - Category: Endocrinology Source Type: research
More News: Acromegaly | American Health | Brain | Endocrinology | Genetics | Lessons | Neurology | Neuroscience | Neurosurgery